Venetoclax for AML: changing the treatment paradigm
Abstract: Venetoclax is a specific B-cell lymphoma-2 (BCL-2) inhibitor that can restore activation of apoptosis in malignancies, the survival of which depends on dysregulation of this pathway. Preclinical data, using various model systems including cell lines and patient samples, suggested targeting...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2019-12-01
|
| Col·lecció: | Blood Advances |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S2473952920317213 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|